SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form F-3 - Registration statement by foreign private issuers:
SEC Accession No. 0001213900-19-011719
Filing Date
2019-06-28
Accepted
2019-06-28 09:48:50
Documents
6

Document Format Files

Seq Description Document Type Size
1 REGISTRATION STATEMENT ff32019_enlivextherapeutics.htm F-3 235996
2 OPINION OF YIGAL ARNON & CO. ff32019ex5-1_enlivextherap.htm EX-5.1 30926
3 CONSENT OF YAREL + PARTNERS, INDEPENDENT REGISTERED CERTIFIED PUBLIC ACCOUNTING ff32019ex23-1_enlivextherap.htm EX-23.1 2176
4 GRAPHIC ex5-1_001.jpg GRAPHIC 16236
5 GRAPHIC ex23-1_001.jpg GRAPHIC 21724
6 GRAPHIC img_001.jpg GRAPHIC 7392
  Complete submission text file 0001213900-19-011719.txt   333186
Mailing Address 37 DEREH MENACHEM BEGIN ST. 15TH FLOOR TEL AVIV L3 6522042
Business Address 37 DEREH MENACHEM BEGIN ST. 15TH FLOOR TEL AVIV L3 6522042 972 (0) 3 7326616
Enlivex Therapeutics Ltd. (Filer) CIK: 0001596812 (see all company filings)

IRS No.: 000000000 | State of Incorp.: L3 | Fiscal Year End: 1231
Type: F-3 | Act: 33 | File No.: 333-232413 | Film No.: 19927579
SIC: 2834 Pharmaceutical Preparations